| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Elston George | Chief Financial Officer | C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN | /s/ Ron Honig, Attorney-in-Fact | 22 Sep 2025 | 0001429932 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EYPT | Common Stock | Gift | $0 | -20,000 | -24% | $0.000000 | 62,114 | 19 Sep 2025 | Direct | F1, F2 |
| transaction | EYPT | Common Stock | Gift | $0 | +20,000 | $0.000000 | 20,000 | 19 Sep 2025 | By Family Trust | F1, F3 |
| Id | Content |
|---|---|
| F1 | On September 19, 2025, the reporting person transferred owned shares of Common Stock of the Company to an irrevocable family trust of which JP Morgan Trust Company of Delaware is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). |
| F2 | Includes 1,266 shares acquired on July 31, 2025, pursuant to EyePoint's 2019 Employee Stock Purchase Plan. |
| F3 | These securities are held in a trust for the benefit of the reporting person's children. JP Morgan Trust Company of Delaware is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |